eRapa™ for the Treatment of Rare Genetic Diseases & Cancer
About Us
About Us
We are commercializing eRapa™,
a novel, targeted formulation of rapamycin, to suppress the onset and recurrence of cancer. Our pipeline includes several early stage cancers or precancerous conditions.
eRapa™
About Us
eRapa™ is a novel formulation of rapamycin that can extend life by delaying the onset of aging-related diseases and can postpone the effects of normal aging.
Cancer Prevention
Cancer Prevention
Leading indication: Familial Adenomatous Polyposis (FAP), a rare genetic disease that leads to colon cancer for which no current therapeutics exist.